“Breaking News: Innate Pharma Initiates Phase 1 Study for Promising Cancer Treatment IPH4502”
First Patient Dosed in Phase 1 Study of Innovative Antibody-Drug Conjugate IPH4502 Introduction Innate Pharma SA has initiated a Phase 1 study to evaluate the safety and tolerability of IPH4502, an Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors expressing Nectin-4. This novel ADC, designed to precisely target Nectin-4, aims to revolutionize the treatment…